Analysts expect Chemours Co (NYSE:CC) to report $1.07 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Chemours’ earnings, with the highest EPS estimate coming in at $1.13 and the lowest estimate coming in at $0.96. Chemours posted earnings of $1.19 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 10.1%. The company is scheduled to issue its next quarterly earnings results on Wednesday, February 13th.
On average, analysts expect that Chemours will report full-year earnings of $5.69 per share for the current financial year, with EPS estimates ranging from $5.57 to $5.80. For the next fiscal year, analysts anticipate that the firm will report earnings of $5.57 per share, with EPS estimates ranging from $5.04 to $6.00. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Chemours.
Chemours (NYSE:CC) last issued its quarterly earnings data on Thursday, November 1st. The specialty chemicals company reported $1.49 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.07. The firm had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.71 billion. Chemours had a return on equity of 106.98% and a net margin of 16.02%. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.12 EPS.
Several equities analysts recently issued reports on the company. Morgan Stanley dropped their price target on Chemours from $48.00 to $47.00 and set a “hold” rating on the stock in a research report on Tuesday, September 25th. Barclays reissued a “buy” rating and set a $62.00 price target on shares of Chemours in a research note on Tuesday, August 7th. SunTrust Banks decreased their price target on Chemours to $38.00 and set a “hold” rating on the stock in a research note on Monday. Citigroup lowered Chemours from a “buy” rating to a “neutral” rating and reduced their target price for the company from $44.00 to $38.00 in a research note on Friday, November 2nd. Finally, BMO Capital Markets reduced their target price on Chemours from $70.00 to $68.00 and set an “outperform” rating on the stock in a research note on Monday, August 6th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $52.60.
A number of institutional investors have recently bought and sold shares of CC. Trilogy Capital Inc. acquired a new stake in shares of Chemours during the 3rd quarter valued at $179,000. Gofen & Glossberg LLC IL bought a new position in shares of Chemours during the 2nd quarter valued at $204,000. Gideon Capital Advisors Inc. bought a new position in Chemours in the 2nd quarter worth $209,000. Signition LP bought a new position in Chemours in the 3rd quarter worth $232,000. Finally, Quantitative Systematic Strategies LLC bought a new position in Chemours in the 2nd quarter worth $247,000. 76.33% of the stock is owned by hedge funds and other institutional investors.
NYSE:CC traded down $0.81 during midday trading on Friday, reaching $32.09. The company had a trading volume of 1,478,134 shares, compared to its average volume of 1,699,240. The firm has a market cap of $5.81 billion, a PE ratio of 8.40, a price-to-earnings-growth ratio of 0.38 and a beta of 2.74. Chemours has a 12-month low of $30.92 and a 12-month high of $54.62. The company has a current ratio of 2.03, a quick ratio of 1.39 and a debt-to-equity ratio of 3.48.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Shareholders of record on Friday, November 16th will be given a $0.25 dividend. The ex-dividend date is Thursday, November 15th. This represents a $1.00 annualized dividend and a yield of 3.12%. Chemours’s dividend payout ratio (DPR) is 26.18%.
Chemours Company Profile
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.
Further Reading: Google Finance
Get a free copy of the Zacks research report on Chemours (CC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.